Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert M Kim

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Journal of Electrocardiology|April 30, 2008
BradycardiaAlbert M Kim, Nora Goldschlager
Journal of Electrocardiology|April 30, 2008
Pseudoventricular fibrillationAlbert M Kim, Nora Goldschlager
Heart Rhythm|May 27, 2009
Microfibrosis and complex fractionated atrial electrogramsAlbert M Kim, Jeffrey E Olgin
Journal of Cardiovascular Electrophysiology|February 12, 2009
Remote navigation guided ablation of incessant atrial tachycardia in a patient with restricted venous accessAlbert M Kim, Nitish Badhwar, Randall J Lee
Heart Rhythm|July 28, 2009
Role of atrial substrate and spatiotemporal organization in atrial fibrillationAlbert M Kim, Jeffrey E Olgin, Thomas H Everett
American Journal of Physiology. Heart and Circulatory Physiology|July 13, 2010
Arrhythmogenesis by single ectopic beats originating in the Purkinje systemMakarand Deo, Patrick M Boyle, Albert M Kim, et al.
Health Science Reports|January 10, 2019
Pharmacokinetics, pharmacodynamics, and safety of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, in healthy subjects when administered in co-mixture with recombinant human hyaluronidase: A phase 1 randomized trialAlmasa Bass, Anna Plotka, Khurshid Mridha, et al.
Frontiers in Pharmacology|February 4, 2012
Cardiac Safety Implications of hNav1.5 Blockade and a Framework for Pre-Clinical EvaluationGül Erdemli, Albert M Kim, Haisong Ju, et al.
Diabetes, Obesity & Metabolism|December 14, 2022
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetesAditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, et al.
Nature Medicine|June 15, 2021
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trialAditi R Saxena, Donal N Gorman, Ryan M Esquejo, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Journal of Electrocardiology|April 30, 2008
BradycardiaAlbert M Kim, Nora Goldschlager
Journal of Electrocardiology|April 30, 2008
Pseudoventricular fibrillationAlbert M Kim, Nora Goldschlager
Heart Rhythm|May 27, 2009
Microfibrosis and complex fractionated atrial electrogramsAlbert M Kim, Jeffrey E Olgin
Journal of Cardiovascular Electrophysiology|February 12, 2009
Remote navigation guided ablation of incessant atrial tachycardia in a patient with restricted venous accessAlbert M Kim, Nitish Badhwar, Randall J Lee
Heart Rhythm|July 28, 2009
Role of atrial substrate and spatiotemporal organization in atrial fibrillationAlbert M Kim, Jeffrey E Olgin, Thomas H Everett
American Journal of Physiology. Heart and Circulatory Physiology|July 13, 2010
Arrhythmogenesis by single ectopic beats originating in the Purkinje systemMakarand Deo, Patrick M Boyle, Albert M Kim, et al.
Health Science Reports|January 10, 2019
Pharmacokinetics, pharmacodynamics, and safety of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, in healthy subjects when administered in co-mixture with recombinant human hyaluronidase: A phase 1 randomized trialAlmasa Bass, Anna Plotka, Khurshid Mridha, et al.
Frontiers in Pharmacology|February 4, 2012
Cardiac Safety Implications of hNav1.5 Blockade and a Framework for Pre-Clinical EvaluationGül Erdemli, Albert M Kim, Haisong Ju, et al.
Diabetes, Obesity & Metabolism|December 14, 2022
A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetesAditi R Saxena, Stephanie-An Lyle, Kaivan Khavandi, et al.
Nature Medicine|June 15, 2021
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trialAditi R Saxena, Donal N Gorman, Ryan M Esquejo, et al.
Pageof 3